Could a simple injection prevent preeclampsia? early trial begins

NCT ID NCT06924385

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety and tolerability of telpegfilgrastim injections in 18 non-pregnant women, including some with a history of preeclampsia. Researchers monitored side effects, drug levels in the blood, and immune markers. The goal is to see if the drug is safe enough to study further for preventing preeclampsia.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
telpegfilgrastim injection
What this could lead to
If successful, this could point toward a treatment to prevent or manage preeclampsia in at-risk women.
What could go wrong
This is a very early Phase 1a safety study with only 18 participants, so it's too soon to know if it works. The drug may cause side effects or fail in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University Third Hospital

    Beijin, Beijing Municipality, 100191, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.